Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIPOSA: AD109 and AD504 in Obstructive Sleep Apnea
NCT05071612Phase 2Completed
- Sponsor
- Apnimed, Inc.
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AD109, atomoxetine + trazodone in obstructive sleep apnea (OSA), sponsored by Apnimed, Inc.. Started Nov 2021; status: completed.
02
Drugs
AD109atomoxetine + trazodone
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05071612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071612.